Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Transl Oncol ; 46: 102003, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38838438

RESUMO

METHODS: One-hundred-six patients diagnosed with non-muscle invasive bladder cancer and treated with intravesical BCG were included and divided into two groups, BCG-responsive (n = 47) and -unresponsive (n = 59). Immunohistochemistry was used to evaluate PD-L1 expression and MSI was assessed by a commercial multiplex PCR kit. The mRNA expression profile of 15 immune checkpoints was performed using the nCounter technology. For in silico validation, two distinct cohorts sourced from the Gene Expression Omnibus (GEO) database were used. RESULTS: Among the 106 patients, only one (<1 %) exhibited MSI instability. PD-L1 expression was present in 9.4 % of cases, and no association was found with BCG-responsive status. We found low gene expression of canonic actionable immune checkpoints PDCD1 (PD-1), CD274 (PD-L1), and CTLA4, while high expression was observed for CD276 (B7-H3), CD47, TNFRSF14, IDO1 and PVR (CD155) genes. High IDO1 expression levels was associated with worst overall survival. The PDCD1, CTLA4 and TNFRSF14 expression levels were associated with BCG responsiveness, whereas TIGIT and CD276 were associated with unresponsiveness. Finally, CD276 was validated in silico cohorts. CONCLUSION: In NMIBC, MSI is rare and PD-L1 expression is present in a small subset of cases. Expression levels of PDCD1, CTLA4, TNFRSF14, TIGIT and CD276 could constitute predictive biomarkers of BCG responsiveness.

2.
Sci Transl Med ; 15(683): eade6023, 2023 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-36791210

RESUMO

The emergence of the SARS-CoV-2 Omicron sublineages resulted in increased transmission rates and reduced protection from vaccines. To counteract these effects, multiple booster strategies were used in different countries, although data comparing their efficiency in improving protective immunity remain sparse, especially among vulnerable populations, including older adults. The inactivated CoronaVac vaccine was among the most widely distributed vaccine worldwide and was essential in the early control of SARS-CoV-2-related hospitalizations and deaths. However, it is not well understood whether homologous versus heterologous booster doses in those fully vaccinated with CoronaVac induce distinct humoral responses or whether these responses vary across age groups. We analyzed plasma antibody responses from CoronaVac-vaccinated younger or older individuals who received a homologous CoronaVac or heterologous BNT162b2 or ChAdOx1 booster vaccine. All three evaluated boosters resulted in increased virus-specific IgG titers 28 days after the booster dose. However, we found that both IgG titers against SARS-CoV-2 Spike or RBD and neutralization titers against Omicron sublineages were substantially reduced in participants who received homologous CoronaVac compared with the heterologous BNT162b2 or ChAdOx1 booster. This effect was specifically prominent in recipients >50 years of age. In this group, the CoronaVac booster induced low virus-specific IgG titers and failed to elevate neutralization titers against any Omicron sublineage. Our results point to the notable inefficiency of CoronaVac immunization and boosting in mounting protective antiviral humoral immunity, particularly among older adults, during the Omicron wave. These observations also point to benefits of heterologous regimens in high-risk populations fully vaccinated with CoronaVac.


Assuntos
Formação de Anticorpos , COVID-19 , Humanos , Idoso , Vacina BNT162 , SARS-CoV-2 , Imunoglobulina G , Anticorpos Antivirais
3.
Int J Mol Sci ; 22(5)2021 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-33668731

RESUMO

Somatic copy number aberrations (CNAs) have been associated with clear-cell renal carcinoma (ccRCC) pathogenesis and are a potential source of new diagnostic, prognostic and therapeutic biomarkers. Recurrent CNAs include loss of chromosome arms 3p, 14q, 9p, and gains of 5q and 8q. Some of these regional CNAs are suspected of altering gene expression and could influence clinical outcomes. Despite many studies of CNAs in RCC, there are currently no descriptions of genomic copy number alterations in a Brazilian ccRCC cohort. This study was designed to evaluate the chromosomal profile of CNAs in Brazilian ccRCC tumors and explore clinical associations. A total of 92 ccRCC Brazilian patients that underwent nephrectomy at Barretos Cancer Hospital were analyzed for CNAs by array comparative genomic hybridization. Most patients in the cohort had early-stage localized disease. The most significant alterations were loss of 3p (87.3%), 14q (35.8%), 6q (29.3%), 9p (28.6%) and 10q (25.0%), and gains of 5q (59.7%), 7p (29.3%) and 16q (20.6%). Bioinformatics analysis revealed 19 genes mapping to CNA significant regions, including SETD2, BAP1, FLT4, PTEN, FGFR4 and NSD1. Moreover, gain of 5q34-q35.3 (FLT4 and NSD1) and loss of 6q23.2-q23.3 (MYB) and 9p21.3 (MLLT3) had gene expression levels that correlated with TCGA data and was also associated with advanced disease features, such as larger tumors, Fuhrman 3, metastasis at diagnosis and death. The loss of region 14q22.1 which encompasses the NIN gene was associated with poor overall survival. Overall, this study provides the first CNA landscape of Brazilian patients and pinpoints genomic regions and specific genes worthy of more detailed investigations. Our results highlight important genes that are associated with copy number changes involving large chromosomal regions that are potentially related to ccRCC tumorigenesis and disease biology for future clinical investigations.


Assuntos
Carcinoma de Células Renais/genética , Variações do Número de Cópias de DNA/genética , Neoplasias Renais/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil , Cromossomos Humanos Par 14/genética , Simulação por Computador , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Análise de Sobrevida , Transcriptoma/genética , Adulto Jovem
4.
Urol Oncol ; 36(1): 11.e13-11.e21, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28986088

RESUMO

BACKGROUND: Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-line therapy for metastatic RCC (mRCC), with significant improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib. OBJECTIVE: To study the expression of AXL in a series patients with of mRCC treated with sunitinib and to correlate it with patient's clinic-pathological features and therapeutic response. MATERIAL AND METHODS: Sixty-four patients with mRCC (51 clear cell carcinomas (CCCs) and 13 non-CCCs) were evaluated for AXL expression by immunohistochemistry in the primary tumor. RESULTS: AXL positivity was observed in 47% (30/64) of cases, namely in 43% (22/51) of CCCs and 61% (8/13) of non-CCC. Considering only the clear cell subtype, the univariate analysis showed that AXL expression was statistically associated with a poor prognosis, with a median overall survival of 13 months vs. 43 months in patients with negative AXL. In this subtype, along with the AXL positivity, other prognostic factors were absence of nephrectomy, Karnofsky performance status, more than 1 site of metastasis and liver metastasis. Moreover, AXL expression was associated with shorter progression to sunitinib. Overall, the multivariate survival analysis showed that absence of nephrectomy (HR = 4.85, P = 0.001), more than 1 site of metastasis (HR = 2.99, P = 0.002), bone metastasis (HR = 2.95, P = 0.001), together with AXL expression (HR = 2.01, P = 0.048) were independent poor prognostic factor in patients with mRCC. CONCLUSION: AXL expression was associated with worse clinical outcome and may be an important prognostic biomarker in sunitinib-treated patients with metastatic renal cell carcinoma.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Imuno-Histoquímica/métodos , Indóis/uso terapêutico , Pirróis/uso terapêutico , Receptores Proteína Tirosina Quinases/metabolismo , Antineoplásicos/farmacologia , Carcinoma de Células Renais/patologia , Feminino , Humanos , Indóis/farmacologia , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Pirróis/farmacologia , Sunitinibe , Resultado do Tratamento
5.
Barretos; s.n; 2016. ilus, map, tab, graf.
Tese em Português | Inca | ID: biblio-943093

RESUMO

JUSTIFICATIVA: Carcinoma de células renais representa 2-3% de todos dos cânceres. Em 2012, a incidência de câncer de rim no Brasil foi de 6.200 brasileiros, e metade desses pacientes morreram da doença naquele ano. Novas terapias alvo-moleculares, como o sunitinibe, emergiram nos últimos anos para pacientes com câncer de rim metastático, com aumento de sobrevida global. No entanto, existe uma grande heterogeneidade inter-paciente e falta de biomarcadores específicos preditivos de resposta terapêutica ou fatores prognósticos. Estudos recentes, inclusive do nosso grupo tem sugerido que a expressão do receptor de tirosina-quinase AXL, pode condicionar a resposta ao sunitinibe. OBJETIVOS: Avaliar a expressão proteica de AXL através da técnica de imuno-histoquímica em 114 pacientes com carcinoma de células renais metastático tratados com sunitinibe no Hospital de Câncer de Barretos, e correlacionar o perfil de expressão com as características clínicas e patológicas e resposta terapêutica ao uso desta medicação. MATERIAIS E MÉTODOS: Através de análise retrospectiva de prontuários desses pacientes, determinar o perfil epidemiológico e características clínicas e patológicas. Revisão histopatológica dos casos e realização de um tissue microarray (TMA) dos casos selecionados, contendo tecido normal, tumor primário e metastático renal para posterior análise de expressão proteica. Após a otimização da técnica de imuno-histoquímica para a proteína AXL, procedemos à avaliação da sua expressão. Por último, correlacionamos o perfil de expressão de AXL com as características epidemiológicas e clínico-patológicas dos pacientes, em particular o seu impacto no prognóstico e resposta terapêutica ao uso desta medicação...


BACKGROUND: Renal cell carcinoma represents 2-3% of all cancers of the Western countries. In 2012 it was estimated that the incidence of kidney cancer in Brazil was approximately in 6,200 Brazilians, and half of these patients died from the disease that year. New targeted molecular therapies emerged in recent years for patients with metastatic kidney cancer, with objective tumor responses in approximately 30%, with a significant increase in overall survival. However, there is great heterogeneity inter-patient and the lack of predictive or prognostic biomarkers. The search for those biomarkers aims to better characterize the patient with kidney cancer and provide a more sensitive guide to medical management. Recent studies in our group have even suggested that the expression of tyrosine kinase AXL receptor may affect the response to the molecular target drug, sunitinib, currently used in the treatment of patients with renal cell carcinoma. OBJECTIVE: To evaluate the protein expression of AXL by immunohistochemistry technique in 114 patients with metastatic renal cell carcinoma treated with sunitinib in Barretos Cancer Hospital, and to correlate the expression profile with clinical and pathological features and therapeutic response to use of this medication. MATERIALS AND METHODS: To determine the epidemiological and clinical and pathological characteristics of patients with metastatic renal cell carcinoma who have made use of sunitinib; histopathologic review of cases and conducting a tissue-microarray (TMA) of the selected cases; optimizing the immunohistochemistry technique to evaluate the AXL protein and its expression; correlate the profile AXL expression with the epidemiological and clinical-pathological characteristics of the patients, in particular its impact on prognosis and therapeutic response to this drug...


Assuntos
Masculino , Feminino , Humanos , Biomarcadores Farmacológicos , Biomarcadores Tumorais , Carcinoma de Células Renais , Imuno-Histoquímica , Neoplasias Renais , Proteínas Tirosina Quinases
6.
Exp Cell Res ; 332(1): 1-10, 2015 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-25637219

RESUMO

Receptor tyrosine kinase (RTK) targeted therapy has been explored for glioblastoma treatment. However, it is unclear which RTK inhibitors are the most effective and there are no predictive biomarkers available. We recently identified the RTK AXL as a putative target for the pan-RTK inhibitors cediranib and sunitinib, which are under clinical trials for glioblastoma patients. Here, we provide evidence that AXL activity can modulate sunitinib response in glioblastoma cell lines. We found that AXL knockdown conferred lower sensitivity to sunitinib by rescuing migratory defects and inhibiting apoptosis in cells expressing high AXL basal levels. Accordingly, overactivation of AXL by its ligand GAS6 rendered AXL positive glioblastoma cells more sensitive to sunitinib. AXL knockdown induced a cellular rewiring of several growth signaling pathways through activation of RTKs, such as EGFR, as well as intracellular pathways such as MAPK and AKT. The combination of sunitinib with a specific AKT inhibitor reverted the resistance of AXL-silenced cells to sunitinib. Together, our results suggest that sunitinib inhibits AXL and AXL activation status modulates therapy response of glioblastoma cells to sunitinib. Moreover, it indicates that combining sunitinib therapy with AKT pathway inhibitors could overcome sunitinib resistance.


Assuntos
Inibidores da Angiogênese/farmacologia , Indóis/farmacologia , Proteínas Proto-Oncogênicas/fisiologia , Pirróis/farmacologia , Receptores Proteína Tirosina Quinases/fisiologia , Linhagem Celular Tumoral , Movimento Celular , Sobrevivência Celular/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos , Ensaios de Seleção de Medicamentos Antitumorais , Sinergismo Farmacológico , Ativação Enzimática , Receptores ErbB/metabolismo , Técnicas de Silenciamento de Genes , Glioblastoma , Compostos Heterocíclicos com 3 Anéis/farmacologia , Humanos , Transdução de Sinais , Sunitinibe , Receptor Tirosina Quinase Axl
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA